Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians.
Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions.
The company’s lead product, TTI-101, is currently being studied in a first-in-man Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. To date, TTI-101 has demonstrated an excellent safety profile and clinical activity.
Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.